Showing results (1-10 of 192) with videos related to
Sort By:
Pageof 20
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie ShanmuganathanHematology. American Society of Hematology. Education Program|December 4, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P HughesCurrent Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P HughesHematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P HughesBlood|November 16, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P HughesBritish Journal of Haematology|June 22, 2022
Asciminib for chronic myeloid leukaemia: Next questionsNaranie Shanmuganathan, Timothy P HughesAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 24, 2025
Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?Naranie Shanmuganathan, Michael Osborn, Timothy P HughesBlood|April 25, 2022
Asciminib: a new therapeutic option in chronic-phase CML with treatment failureDavid T Yeung, Naranie Shanmuganathan, Timothy P HughesExpert Review of Hematology|July 10, 2025
How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?Jessica Sia, Naranie ShanmuganathanBritish Journal of Haematology|September 18, 2024
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemiaNaranie Shanmuganathan, Andrew GriggPageof 20